Abstract

Interacting with pharma Open Innovation, What to Expect and What is Expected

Niclas Nilsson, Open Innovation Manager, LEO Pharma

In order to boost pre-competitive collaborations between Academia and the Pharma industry, LEO Pharma has created an open innovation platform allowing external partners access to early drug research tools. The primary intention is to lower the barrier in order to create scientific data by testing external partner’s early, advanced or tool compounds in disease-relevant in vitro assays. The assays provide an initial stepping stone that could lead to more advanced collaborations. The platform is focused on identifying novel treatments related to inflammation and dermatology. In this early collaboration-exploring phase there are no binding contracts, no disclosure of any confidential information, it is all for free and data returned to the partner. The presentation will describe the science behind the assays and how it can be used for joint drug research by addressing the following points: What is open innovation? • LEO Pharma open innovation platform as a concrete example • The science behind the disease-relevant in vitro assays • Mutual benefits – what to expect and how to interact For background material the web portal can be found at: http://openinnovation.leo-pharma.com